Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06901245 · ClinicalTrials.gov registry record · Phase 4
Tirzepatide in PWS, HO and GNSO
A Phase 4 study of Prader-Willi Syndrome and Hypothalamic Obesity, sponsored by Grace Kim.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT06901245: Recruiting Phase 4 study of Prader-Willi Syndrome and Hypothalamic Obesity, sponsored by Grace Kim.
NCT06901245 is a Phase 4 study of Prader-Willi Syndrome and Hypothalamic Obesity that is actively recruiting participants, run by Grace Kim. The registered enrollment target is 36 participants, below the 69-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (48% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06901245, a Phase 4 study of Prader-Willi Syndrome and Hypothalamic Obesity, is actively recruiting participants, sponsored by Grace Kim.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Primary Outcome
Weight will be measured in kilograms through anthropometric measurements. Change in percent weight from baseline to week 48 of treatment with tirzepatide in young adults with PWS, HO, GNSO and obesity will then be assessed.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (3)
Minnesota
- Children's Minnesota - Saint Paul
Tennessee
- Vanderbilt University Medical Center - Nashville
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What NCT06901245 shows while recruiting
NCT06901245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 69-participant average among 16 other Prader-Willi Syndrome trials with a reported enrollment target (48% lower).
The record links to 3 conditions, with Prader-Willi Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06901245 reports a single indexed study location in Minnesota, Tennessee, Washington.
Frequently Asked Questions
What is clinical trial NCT06901245 about?
NCT06901245 is a clinical study titled "Tirzepatide in PWS, HO and GNSO". This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be...
What is the current status of trial NCT06901245?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2025-05-01. Estimated completion is 2026-12.
What conditions does trial NCT06901245 study?
This clinical trial studies the following conditions: Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy.
What interventions are being tested in trial NCT06901245?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06901245?
This trial is sponsored by Grace Kim, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06901245 being conducted?
This trial has 3 study locations across Minnesota, Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prader-Willi Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06901245's enrollment target sits among peer trials
36 7th of 16 higher than 10 of 16 other Prader-Willi Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prader-Willi Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
RECRUITING · Phase 3
-
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
RECRUITING · Phase 1
-
Cerebellar TMS and Satiety in Prader-Willi Syndrome
RECRUITING · NA
-
A Study of Pitolisant in Patients With Prader-Willi Syndrome
RECRUITING · Phase 3
-
Impact of Bright Light Therapy on Prader-Willi Syndrome
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI